Paper29252124
Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors.
Thomas A and 23 others. J Clin Oncol, 2018. Cited by 150 papers, by iCite.
Cite this record
ConductScience Library. Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors. Papers, record 29252124. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29252124
- Disease
- small cell lung carcinoma367 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Isoxazoles | Major topic |
| Pyrazines | Major topic |
| Topotecan | Major topic |
| Adult | |
| Aged | |
| Dose-Response Relationship, Drug | |
| Drug Administration Schedule | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Treatment Outcome |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| ZIA BC011746 | Intramural NIH HHS | United States | ZIABC011746 | PubMed | NIH RePORTER |
| ZIA BC011793 | Intramural NIH HHS | United States | ZIABC011793 | PubMed | NIH RePORTER |
| ZICSC006743 | NIH | NIH RePORTER | |||
| ZIEBC011653 | NIH | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT02487095 | Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers | Results | Yes |
Source ClinicalTrials.gov
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 29369707 | Ataxia Telangiectasia-Mutated and Rad3-Related Inhibition and Topoisomerase I Trapping Create a Synthetic Lethality in Cancer Cells. | https://conductscience.org/library/papers/29369707 |
Source PubMed
References32
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23451157 | Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells. | PLoS One | 2013 | https://conductscience.org/library/papers/23451157 | PubMed |
| 2 | 22120667 | Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. | Nat Struct Mol Biol | 2011 | https://conductscience.org/library/papers/22120667 | PubMed |
| 3 | 19553641 | Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. | N Engl J Med | 2009 | https://conductscience.org/library/papers/19553641 | PubMed |
| 4 | 11673449 | Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress. | J Biol Chem | 2001 | https://conductscience.org/library/papers/11673449 | PubMed |
| 5 | 28714480 | The impact of replication stress on replication dynamics and DNA damage in vertebrate cells. | Nat Rev Genet | 2017 | https://conductscience.org/library/papers/28714480 | PubMed |
| 6 | 22713662 | Targeting radiation-resistant hypoxic tumour cells through ATR inhibition. | Br J Cancer | 2012 | https://conductscience.org/library/papers/22713662 | PubMed |
| 7 | 25269479 | ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. | Cancer Res | 2014 | https://conductscience.org/library/papers/25269479 | PubMed |
| 8 | 21098704 | Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. | Cancer Res | 2010 | https://conductscience.org/library/papers/21098704 | PubMed |
| 9 | 24366029 | Causes and consequences of replication stress. | Nat Cell Biol | 2014 | https://conductscience.org/library/papers/24366029 | PubMed |
| 10 | 27958275 | ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. | Nat Commun | 2016 | https://conductscience.org/library/papers/27958275 | PubMed |
| 11 | 16990856 | Topoisomerase I inhibitors: camptothecins and beyond. | Nat Rev Cancer | 2006 | https://conductscience.org/library/papers/16990856 | PubMed |
| 12 | 23222511 | Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. | Cell Death Dis | 2012 | https://conductscience.org/library/papers/23222511 | PubMed |
| 13 | 28698210 | APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition. | Cancer Res | 2017 | https://conductscience.org/library/papers/28698210 | PubMed |
| 14 | 11121462 | Protection of normal proliferating cells against chemotherapy by staurosporine-mediated, selective, and reversible G(1) arrest. | J Natl Cancer Inst | 2000 | https://conductscience.org/library/papers/11121462 | PubMed |
| 15 | 28069806 | DNA-Containing Exosomes Derived from Cancer Cells Treated with Topotecan Activate a STING-Dependent Pathway and Reinforce Antitumor Immunity. | J Immunol | 2017 | https://conductscience.org/library/papers/28069806 | PubMed |
| 16 | 27067599 | A Genome-wide CRISPR Screen Identifies CDC25A as a Determinant of Sensitivity to ATR Inhibitors. | Mol Cell | 2016 | https://conductscience.org/library/papers/27067599 | PubMed |
| 17 | 25281304 | DNA replication stress: causes, resolution and disease. | Exp Cell Res | 2014 | https://conductscience.org/library/papers/25281304 | PubMed |
| 18 | 26486755 | Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients. | Sci Rep | 2015 | https://conductscience.org/library/papers/26486755 | PubMed |
| 19 | 21552262 | A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. | Nat Struct Mol Biol | 2011 | https://conductscience.org/library/papers/21552262 | PubMed |
| 20 | 21325706 | Recent developments in the use of γ-H2AX as a quantitative DNA double-strand break biomarker. | Aging (Albany NY) | 2011 | https://conductscience.org/library/papers/21325706 | PubMed |
Cited by112
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 150 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42816529 | Safety and efficacy of ceralasertib, an ATR kinase inhibitor, combined with olaparib: dose escalation in advanced solid tumours and dose expansion in advanced breast cancer. | Br J Cancer | 2026 | https://conductscience.org/library/papers/42816529 | PubMed |
| 42778539 | Synthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translation. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42778539 | PubMed |
| 42410700 | Duocarmycin-Bearing Antibody-Mimetic Drug Conjugate Combined With an ATR Inhibitor Results in Complete Tumor Regression in a KPL-4 Xenograft Model. | Cancer Med | 2026 | https://conductscience.org/library/papers/42410700 | PubMed |
| 42232064 | Multi-omics dissection of R-loop dynamics in tumorigenesis: From transcription-replication conflict to therapeutic targets. | Mol Ther Oncol | 2026 | https://conductscience.org/library/papers/42232064 | PubMed |
| 42098732 | Synthetic lethality in cancer: mechanism exploration and therapeutic applications. | Cell Commun Signal | 2026 | https://conductscience.org/library/papers/42098732 | PubMed |
| 42092629 | Molecular Determinants of Response and Rational Drug Combinations for Antibody-Drug Conjugates (ADCs) with Topoisomerase I (TOP1) Inhibitor Payloads. | J Mol Biol | 2026 | https://conductscience.org/library/papers/42092629 | PubMed |
| 41896265 | Elimusertib enhances cytotoxic effects of conventional chemotherapy and sensitizes to radiation in preclinical Ewing sarcoma models. | Sci Rep | 2026 | https://conductscience.org/library/papers/41896265 | PubMed |
| 41862351 | Replication origin flexibility: a tool to mitigate the hazards of excess replication. | Trends Genet | 2026 | https://conductscience.org/library/papers/41862351 | PubMed |
| 41823504 | A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950). | Cancer | 2026 | https://conductscience.org/library/papers/41823504 | PubMed |
| 41575477 | Palladium-catalyzed Suzuki-Miyaura and Buchwald-Hartwig cross-coupling reactions towards the synthesis of pharmacologically potent pyrimidine-based molecules. | Mol Divers | 2026 | https://conductscience.org/library/papers/41575477 | PubMed |
| 41421295 | A phase II, multicenter, open-label, single-arm study of berzosertib plus topotecan in patients with relapsed platinum-resistant small-cell lung cancer (DDRiver SCLC 250). | ESMO Open | 2026 | https://conductscience.org/library/papers/41421295 | PubMed |
| 41409249 | The efficacy and safety of ATR inhibitors in the treatment of solid tumors: a systematic review and meta-analysis. | Front Oncol | 2025 | https://conductscience.org/library/papers/41409249 | PubMed |
| 41335461 | NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancer. | Oncologist | 2025 | https://conductscience.org/library/papers/41335461 | PubMed |
| 41190241 | Targeting DNA repair mechanisms in cancer therapy: the role of small molecule DNA repair inhibitors. | NAR Cancer | 2025 | https://conductscience.org/library/papers/41190241 | PubMed |
| 41160399 | Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938). | Cancer | 2025 | https://conductscience.org/library/papers/41160399 | PubMed |
| 41105363 | Deciphering TICRR's oncogenic landscape in pancreatic adenocarcinoma: molecular insights and clinical implications. | Discov Oncol | 2025 | https://conductscience.org/library/papers/41105363 | PubMed |
| 40859871 | Synthetic Lethality-Based Targets and Their Exploration in Tumour Combination Strategies. | J Cell Mol Med | 2025 | https://conductscience.org/library/papers/40859871 | PubMed |
| 40848933 | Targeting DNA Topoisomerase I for the Treatment of Cancer: Past, Present and Future. | J Mol Biol | 2026 | https://conductscience.org/library/papers/40848933 | PubMed |
| 40523990 | Advancing therapeutics in small-cell lung cancer. | Nat Cancer | 2025 | https://conductscience.org/library/papers/40523990 | PubMed |
| 40437704 | Microtracer-Based Assessment of the Mass Balance, Pharmacokinetics, and Excretion of [14C]Berzosertib, an Intravenous ATR Inhibitor, in Patients With Advanced Solid Tumors: A Phase 1 Study. | Clin Pharmacol Drug Dev | 2025 | https://conductscience.org/library/papers/40437704 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ATR | 545 | PubTator's text mining | https://conductscience.org/library/genes/545 | NCBI Gene |
| TOP1 | 7150 | PubTator's text mining | https://conductscience.org/library/genes/7150 | NCBI Gene |
Drugs2
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| BERZOSERTIB | CHEMBL3989870 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL3989870 | ChEMBL |
| TOPOTECAN | CHEMBL84 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL84 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29252124
GET https://conductscience.org/api/papers/v1/29252124/authors?page=2